Prevention of the secondary cerebral organ damage by stimulation of the AT2-receptor and the receptor Mas in a model of acute lung injury

刺激AT2受体和Mas受体预防急性肺损伤模型继发性脑器官损伤

基本信息

项目摘要

This project evaluates the therapeutic potential of a direct stimulation of the AT2 receptor and the receptor Mas on the secondary cerebral organ damage in a model of acute lung injury. Main goal of this project is to demonstrate that pharmacological activation of these two receptors using the specific agonists Compound 21 (C21) and AVE0991 might be a successful, therapeutic strategy in treatment of the acute lung injury on the one hand, and also in prevention of the secondary cerebral organ damage on the other hand. Focus of the project is the characterization of the pulmonary and cerebral inflammation, the quantification of the organ damage and the evaluation of cellular mechanisms involved in cell death and survival such as apoptosis and autophagy. Also, the project aims to describe, at least in part, the underlying signaling pathways via a down-regulation of the ERK-cascade. A distant goal and also the vision of this project is to describe a new, potentially beneficial treatment strategy for patients with acute respiratory distress syndrome. To date, there are no specific pharmacological interventions available to improve outcomes or to attenuate secondary organ damages in these patients. From the clinical perspective, a new intervention strategy for these critically-ill patients would be worthwhile. In this respect, the project comprises fundamental research to this topic. Positive experimental results given, clinical studies could be conducted to evaluate the principle of a AT2/receptor Mas activation in patients with acute lung failure.
本项目评估直接刺激AT2受体和受体Mas对急性肺损伤模型中继发性脑器官损伤的治疗潜力。本项目的主要目的是证明特异性激动剂Compound 21 (C21)和AVE0991对这两种受体的药理激活可能是一种成功的治疗策略,一方面可以治疗急性肺损伤,另一方面可以预防继发性脑器官损伤。项目重点是肺和脑炎症的表征,器官损伤的量化以及细胞凋亡和自噬等细胞死亡和生存机制的评估。此外,该项目旨在描述,至少部分,通过下调erk级联的潜在信号通路。一个遥远的目标,也是这个项目的愿景是描述一个新的,潜在的有益的治疗策略,患者急性呼吸窘迫综合征。到目前为止,还没有特定的药物干预措施可以改善这些患者的预后或减轻继发性器官损伤。从临床角度来看,对这些危重患者采取新的干预策略是值得的。在这方面,本项目包括对本课题的基础研究。如果实验结果为阳性,则可以开展临床研究来评估AT2/受体Mas在急性肺衰竭患者中的激活原理。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Professor Dr. Mario Menk其他文献

Professor Dr. Mario Menk的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

相似海外基金

Novel food-based approach for prevention of age-associated cognitive decline inolder adults with obesity
预防肥胖老年人与年龄相关的认知能力下降的基于食物的新方法
  • 批准号:
    10395140
  • 财政年份:
    2021
  • 资助金额:
    --
  • 项目类别:
Anticoagulation in ICH Survivors for Prevention and Recovery (ASPIRE)
ICH幸存者的抗凝治疗以预防和恢复(ASPIRE)
  • 批准号:
    10170976
  • 财政年份:
    2020
  • 资助金额:
    --
  • 项目类别:
DIAN-TU: Tau Next Generation Prevention Trial
DIAN-TU:Tau 下一代预防试验
  • 批准号:
    10261442
  • 财政年份:
    2020
  • 资助金额:
    --
  • 项目类别:
DIAN-TU: Tau Next Generation Prevention Trial
DIAN-TU:Tau 下一代预防试验
  • 批准号:
    10452692
  • 财政年份:
    2020
  • 资助金额:
    --
  • 项目类别:
DIAN-TU: Tau Next Generation Prevention Trial
DIAN-TU:Tau 下一代预防试验
  • 批准号:
    10035004
  • 财政年份:
    2020
  • 资助金额:
    --
  • 项目类别:
Anticoagulation in ICH Survivors for Prevention and Recovery (ASPIRE)
ICH幸存者的抗凝治疗以预防和恢复(ASPIRE)
  • 批准号:
    10159987
  • 财政年份:
    2019
  • 资助金额:
    --
  • 项目类别:
Investigation into statins as prevention and treatment of inflammation in pregnancy
他汀类药物预防和治疗妊娠期炎症的研究
  • 批准号:
    9975203
  • 财政年份:
    2019
  • 资助金额:
    --
  • 项目类别:
DIAN-TU Primary Prevention Trial
DIAN-TU一级预防试验
  • 批准号:
    9782832
  • 财政年份:
    2018
  • 资助金额:
    --
  • 项目类别:
DIAN-TU Primary Prevention Trial NfL Characterization Admin Supp
DIAN-TU 初级预防试验 NfL 特征管理补充
  • 批准号:
    10619079
  • 财政年份:
    2018
  • 资助金额:
    --
  • 项目类别:
DIAN-TU Primary Prevention Trial
DIAN-TU一级预防试验
  • 批准号:
    10446989
  • 财政年份:
    2018
  • 资助金额:
    --
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了